Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.49 |
| ▸ | NPC1 | O15118 | 7/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3748460 | 0.93 | RAB9A (0.47) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL3746058 | 0.84 | RAB9A (0.44) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL3759165 | 0.83 | ALDH1A1 (0.49) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL27697788 | 0.76 | MEN1 (0.45) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL3756932 | 0.76 | RAB9A (0.46) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL2060733 | 0.73 | ALDH1A1 (0.61) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL31430630 | 0.73 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL13883308 | 0.72 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL8139921 | 0.72 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL5909894 | 0.72 | MAPT (0.46) | SMN1; SMN2MAPTALDH1A1POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902356-B2 | Thiazolopyridinone derivates as MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902356-B2 | Thiazolopyridinone derivates as MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| US-7838543-B2 | Melanin Concentrating Hormone Receptor 1; Obesity; 4'-Fluoro-biphenyl-4-carboxylic acid {2-[(2-dimethylamino-ethyl)-methyl-amino]-benzothiazol-6-yl}amide; 4-Cyclohexyl-N-{2-[(2-dimethylamino-ethyl)-methyl-amino]-benzooxazol-5-yl}-benzamide; 2-aminobenzoxazoles or 2-aminobenzothiazoles | ELI LILLY AND COMPANY (US) | 2010-11-23 | — | — | US | disclosed |
| US-7838543-B2 | Melanin Concentrating Hormone Receptor 1; Obesity; 4'-Fluoro-biphenyl-4-carboxylic acid {2-[(2-dimethylamino-ethyl)-methyl-amino]-benzothiazol-6-yl}amide; 4-Cyclohexyl-N-{2-[(2-dimethylamino-ethyl)-methyl-amino]-benzooxazol-5-yl}-benzamide; 2-aminobenzoxazoles or 2-aminobenzothiazoles | ELI LILLY AND COMPANY (US) | 2010-11-23 | — | — | US | disclosed |
| EP-1828207-B1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-10-28 | — | — | EP | disclosed |
| EP-1828207-B1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-10-28 | — | — | EP | disclosed |
| US-20090233919-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-09-17 | — | — | US | disclosed |
| US-20090233919-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-09-17 | — | — | US | disclosed |
| US-20090170913-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-07-02 | — | — | US | disclosed |
| US-20090170913-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-07-02 | — | — | US | disclosed |
| EP-1828177-B1 | NOVEL MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1828207-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1828177-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006066173-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006066174-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170913-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | RAB9A 1154/4885NPC1 689/4885SMN1; SMN2 2294/4885 |
| US-20090233919-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | RAB9A 1635/4885NPC1 828/4885SMN1; SMN2 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.